Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2019 | Combo of RG6146/venetoclax/rituximab for R/R DLBCL: initial data

Michael Dickinson • 20 Jun 2019
ICML 2019
B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma RG6146 Rituximab Venetoclax

Michael Dickinson, MBBS, DMedSc, FRACP, FRACPA, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the combination of the BET inhibitor RG6146, venetoclax and rituximab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL). He reports the initial Phase Ib safety, biomarker and response data (NCT03255096). This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Michael Dickinson

4:18
Pembrolizumab monotherapy for older/ABVD-ineligible patients with Hodgkin lymphoma
Michael Dickinson • 16 Jun 2023
3:48
COALITION: glofitamab + R-CHOP or glofitamab + pola-R-CHP in high-risk DLBCL
Michael Dickinson • 16 Jun 2023
10:25
Key highlights in NHL: updates in MCL, the role of transplantation, and novel bispecific antibodies
Michael Dickinson et al. • 12 Dec 2022
3:49
The challenges in developing bispecific antibodies for non-Hodgkin lymphoma
Michael Dickinson • 30 Sep 2022

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals